HSP70 Via HIF-1 α SUMOylation Inhibits Ferroptosis Inducing Lung Cancer Recurrence After Insufficient Radiofrequency Ablation
Overview
Authors
Affiliations
Radiofrequency ablation (RFA) is an effective and feasible therapy for lung cancer, but accelerated progression of residual non-small cell lung cancer (NSCLC) after incomplete radiofrequency ablation (RFA) has frequently been reported. A previous study reported that HSP70 and HIF-1α were highly expressed in areas with incomplete RFA. Therefore, we sought to elucidate the regulatory effect of the HIF-1α/HSP70 pathway on lung cancer recurrence after incomplete radiofrequency ablation. In this study, we found that knockdown of HSP70 can reduce sumo 1, sumo 2/3 (marker of SUMOylation) of HIF-1α and inhibit A549 cell proliferation and migration under heat stress conditions (used to simulate incomplete RFA in vitro). We observed that knockdown of HSP70 altered the expression of ferroptosis-related proteins and genes (SLC7A11 and ACSL3), and the RNA-seq results showed that knockdown of HSP70 activated the ferroptosis pathway, further confirming that HSP70 regulates ferroptosis. In summary, HSP70, via HIF-1α SUMOylation, inhibited ferroptosis, inducing lung cancer recurrence after radiofrequency ablation. The study reveals a new direction for further research on therapeutic targets to suppress lung cancer recurrence and provides a theoretical foundation for further clinical studies.
Zhao S, Shen L, Tong X, Jiang X, Li H, Zhao J Cardiovasc Intervent Radiol. 2025; .
PMID: 39994026 DOI: 10.1007/s00270-025-03984-1.
Zhang J, Yao M, Xia S, Zeng F, Liu Q Cell Mol Biol Lett. 2025; 30(1):2.
PMID: 39757165 PMC: 11702238. DOI: 10.1186/s11658-024-00682-7.
Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy.
Youssef E, Zhao S, Purcell C, Olson G, El-Deiry W Front Oncol. 2024; 14:1484515.
PMID: 39697237 PMC: 11652374. DOI: 10.3389/fonc.2024.1484515.
Ferroptosis: principles and significance in health and disease.
Chen F, Kang R, Tang D, Liu J J Hematol Oncol. 2024; 17(1):41.
PMID: 38844964 PMC: 11157757. DOI: 10.1186/s13045-024-01564-3.
Liu J, Zhang G, Li X, Zheng C, Kan X Heliyon. 2024; 10(8):e29866.
PMID: 38681568 PMC: 11053292. DOI: 10.1016/j.heliyon.2024.e29866.